Entasis Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The company's lead product candidate, ETX2514, as well as one of its other product candidates, ETX0282, inhibit one of the most prevalent forms of bacterial resistance, ?-lactamase enzymes, so named because of their ability to inactivate ?-lactam antibiotics. The company's other product candidate, zoliflodacin, targets the validated mechanism of action of the fluoroquinolone class of antibiotics, but does so in a manner to avoid existing fluoroquinolone resistance.

Green Brick Partners is a homebuilding and land development company. The company acquires and develops land, provides land and construction financing to its controlled builders and participates in the profits of its builders. The company is engaged in homebuilding process, including land acquisition and development, entitlements, design, construction, title and mortgage services, marketing and sales and the creation of brand images at its residential neighborhoods and communities. The company sells finished lots to its controlled builders or option lots from third-party developers for its controlled builders' homebuilding operations and provides them with construction financing and strategic planning.

Marker Therapeutics is a clinical-stage immuno-oncology company focusing on the development and commercialization of cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is developing three primary technology platforms: a licensed peptide-based vaccine for the treatment of breast cancers that overexpresses Human Epidermal Growth Factor Receptor 2 (TPIV100/110); a licensed peptide-based vaccine for treating breast and ovarian cancers that overexpress Folate Receptor Alpha (TPIV200); and a wholly-owned nucleic acid-based vaccine technology (PolyStart?) for treatment of various cancers or infectious disease.

MediciNova is a biopharmaceutical company focused on developing small molecule therapeutics for the treatment of diseases. The company is focusing its development activities on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. The company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Option Care Health is a provider of infusion and home care management solutions. The company partners with physicians, hospital systems, payors, pharmaceutical manufacturers and nursing facilities to provide patients access to post-acute care services. Whether in the home, physician office, ambulatory infusion center, nursing facility or other alternate sites of care, the company provides products, services and condition-specific clinical management programs tailored to improve the care of individuals with health conditions such as gastrointestinal abnormalities, infectious diseases, cancer, multiple sclerosis, organ and blood cell transplants, bleeding disorders, immune deficiencies and heart failure.

Rain Industries Limited (RIL) is an India-based company, which is engaged in the business of manufacture and sale of carbon products, chemicals and cement. The Company operates through three segments: Carbon Products, Chemicals and Cement. The Carbon Products segment consists of Calcined Petroleum Coke (CPC), Green Petroleum Coke (GPC), Coal Tar Pitch (CTP), Co-generated Energy and other derivatives of Coal Tar distillation. The Chemicals segment includes the downstream operations of Coal Tar distillation and consists of Resins, Modifiers, Super Plasticizers and other specialty products. The Cement segment includes the manufacture and sale of Cement. The Company markets cement under the Priya Cement segment. The Company's Subsidiaries include Rain Coke Limited, Rain Cements Limited, Renuka Cement Limited, Rain Commodities (USA) Inc., Rain CII Carbon LLC, CII Carbon Corp, RUETGERS Canada Inc. and Handy Chemicals (USA) Ltd.

Tela Bio is a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's products are an innovative solution that integrate multiple layers of minimally-processed biologic material with interwoven polymers in a unique embroidered pattern, which the company refers to as a reinforced tissue matrix. The company serves customers in the United States.